Epidemiology of liver metastases

Horn, Samantha R.; Stoltzfus, Kelsey C.; Lehrer, Eric J.; Dawson, Laura A.; Tchelebi, Leila; Gusani, Niraj J.; Sharma, Navesh K.; Chen, Hanbo; Trifiletti, Daniel M.; Zaorsky, Nicholas G.

doi:10.1016/j.canep.2020.101760

Cited by 178 publications

(118 citation statements)

References 16 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…The lower median survival time is consistent with the reported overall survival time of synchronous colorectal cancer with liver metastasis patients (18.5 months) ( 13 , 14 ). Similarly, another population-based study also revealed that the median overall survival time of SCLM patients is 7 months ( 15 ).…”

Section: Discussionmentioning

confidence: 90%

Predictive Risk Factors and Online Nomograms for Synchronous Colon Cancer With Liver Metastasis

Zhu

Chen

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Objectives To develop and validate predictive nomograms of cancer specific survival (CSS) and overall survival (OS) for synchronous colon cancer with liver metastasis (SCLM) patients. Methods Patients with pathologically diagnosed colon cancer with liver metastasis were retrieved from the SEER database between 2010 and 2015. Only SCLM patients were included. Univariate and multivariate cox regression analyses were conducted to identify the potential predictors of patients’ survival outcomes. The selected variables were integrated to create predictive nomograms via R tools. Furthermore, the concordance index Harrell’s C statistic (C-index) was calculated to describe the discrimination of nomograms. Calibration (1000 bootstrap resamples) curves were plotted to compare the predictions of nomograms with the observed outcomes. Decision curve analysis (DCA) and clinical impact curves were performed to evaluate the clinical effects of nomograms. Results A total of 22,378 SCLM patients were included. The median time of OS and CSS was 13 and 17 months, respectively. The 1-, 2-, and 3-year rate of OS was 50.6, 28.1, and 14.8%, respectively. While the 1-, 2-, and 3-year rate of CSS was 58.7, 36.8, and 22.5%, respectively. SCLM patients with increased age, left primary tumor location, AJCC IVb stage, and no chemotherapy were associated with an obviously reduced OS and CSS. Variables including age, histological grade, T/N/M stage, tumor size, bone/lung metastasis, CEA, surgery of primary site, and chemotherapy were closely related to the prognoses of SCLM patients. Nomograms of OS and CSS were built and displayed online for convenient utilization. The C-index of OS and CSS monograms were 0.74 and 0.73, respectively, indicating relatively good discrimination of the nomograms. The calibration curves suggested a good agreement between the actual observation and the nomogram prediction. DCAs and clinical impact curves reflected favorable potential clinical effects of predictive nomograms. Conclusion Chemotherapy, surgery of primary site, and age were important independent risk factors for the CSS and OS of SCLM patients. We built and validated two reliable nomograms of OS and CSS to predict the prognoses of SCLM patients, which can be accessed online at ( https://predictive-tool.shinyapps.io/CSS-DynNomapp/ ; https://predictive-tool.shinyapps.io/OS-DynNomapp/ ).

show abstract

Section: Discussionmentioning

confidence: 90%

Predictive Risk Factors and Online Nomograms for Synchronous Colon Cancer With Liver Metastasis

Zhu

Chen

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Death certification is reasonably valid in most countries considered, though variable across some of them. Still, it is possible that a small part of deaths was certified as bone or liver cancer; in case of metastatic disease to bone or liver, however we only considered the primary cancer site [47,48].…”

Section: Discussionmentioning

confidence: 99%

Mortality Trends from Urologic Cancers in Europe over the Period 1980–2017 and a Projection to 2025

Bertuccio

Santucci

Carioli

et al. 2021

European Urology Oncology

View full text Add to dashboard Cite

Background: Patterns and trends in urologic cancer mortality still show geographical differences across Europe. Objective: To monitor mortality trends from urologic cancers, including prostate, testis, bladder, and kidney cancers, in Europe. Design, setting, and participants: We carried out a time-trend analysis for 36 European countries using the official World Health Organization database. Outcome measurements and statistical analysis: We extracted the number of deaths and population data over the 1980-2017 period, and calculated age-standardised (world population) mortality rates for each cancer considered, sex, country, and the European Union (EU) as a whole, at all ages; at ages 35-64 yr for prostate, bladder, and kidney cancers; and at ages 20-44 yr for testicular cancer. For selected major countries, we carried out a joinpoint regression analysis to identify significant changes in trends. We also predicted the number of deaths and rates for 2025, using a logarithmic Poisson count data joinpoint regression model. Results and limitations: Prostate cancer mortality in the EU decreased over recent years, reaching a rate of 10.3/100 000 in 2015 and a projected rate of 8.9/100 000 in 2025. Less favourable trends were observed in eastern Europe, though starting from relatively low rates. Testicular cancer mortality declined over time in most countries, however levelling off in northern and western countries, after reaching very low rates. EU testicular cancer mortality rate in 2015 was 0.3/100 000 at all ages and 0.6/100 000 at ages 20-44 yr. Bladder cancer mortality trends were less favourable in central and eastern countries compared to northern and western ones. The EU rates in 2015 were 5.1/100 000 men and 1.1/100 000 women. Kidney cancer mortality showed less favourable trends, with a slight increase in men and stable rates in women over the past decade in the EU. Conclusions: Mortality from prostate, testis, and bladder cancers, but not from kidney cancer, declined in most European countries, with less favourable trends in most eastern countries.

show abstract

“…In addition to therapy before SAbR, sites of metastatic disease may inform about the aggressiveness of the cancer. 32 , 33 , 34 RCC commonly metastasizes to the lung, lymph nodes, bone, liver, and brain. 35 Tumors that metastasize to the bone, liver, and brain have been shown to be associated with worse OS.…”

Section: Discussionmentioning

confidence: 99%

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma

Schoenhals¹,

Mohamad

Christie³

et al. 2021

Advances in Radiation Oncology

View full text Add to dashboard Cite

Purpose: Oligoprogression, defined as limited sites of progression on systemic therapy, in patients with metastatic renal cell carcinoma (mRCC) is not uncommon, possibly because of inter-and intratumoral heterogeneity. We evaluated the effect of stereotactic ablative radiation therapy (SAbR) for longitudinal control of oligoprogressive mRCC. Methods and Materials: Patients with extracranial mRCC were included in this retrospective analysis if they progressed in ≤3 sites on systemic therapy while demonstrating response/stability at other sites and received SAbR to all progressing sites without switching systemic therapy. Our primary endpoint was modified progression-free survival (mPFS), which we calculated from the start of SAbR to the start of a subsequent systemic therapy, death, or loss to follow-up. Results: We identified 36 patients with a median follow-up of 20.4 months (interquartile range, 10.9-29.4). Forty-three sites were treated with SAbR with a median dose of 36 Gy (range, 18-50) in 3 fractions (range, 1-5). Median time to SAbR from the start of systemic therapy was 11.4 months (interquartile range, 6.1-17.1). Median mPFS was 9.2 months (95% confidence interval [CI], 5.9-13.2). Patients receiving SAbR while on immunotherapy exhibited a longer median mPFS (>28.4 months, log-rank P = .0001) than patients not on immunotherapy (9.2 months). Median overall survival from SAbR administration was 43.4 months (95% CI, 21.5-not Reached). The 1-year local control rate was 93% (95% CI, 78.7-97.5). Most SAbR-related toxicities were grade 1 to 2 (33% of patients), with one grade 5 hemoptysis event possibly related to SAbR or disease progression. Conclusions: SAbR has the potential to extend the the duration of current systemic therapy for selected patients with mRCC, preserving subsequent therapies for later administration possibly enabling longer treatment duration.

show abstract

Epidemiology of liver metastases

Cited by 178 publications

References 16 publications

Predictive Risk Factors and Online Nomograms for Synchronous Colon Cancer With Liver Metastasis

Predictive Risk Factors and Online Nomograms for Synchronous Colon Cancer With Liver Metastasis

Mortality Trends from Urologic Cancers in Europe over the Period 1980–2017 and a Projection to 2025

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma

Contact Info

Product

Resources

About